Last update 01 Sep 2025

Ropivacaine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ropivacaine Hydrochloride and Sodium Chloride, Ropivacaine Hydrochloride Hydrate, (-)-LEA-103
+ [19]
Target
Action
modulators
Mechanism
SCNA modulators(Sodium voltage-gated channel alpha subunits modulators)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United Kingdom (22 Apr 1996),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H29ClN2O2
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N
CAS Registry132112-35-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Labor Pain
Australia
27 Feb 2013
Pain, Postoperative
Japan
04 Apr 2001
Acute Pain
Austria
22 Apr 1996
Acute Pain
Belgium
22 Apr 1996
Acute Pain
France
22 Apr 1996
Acute Pain
Germany
22 Apr 1996
Acute Pain
Ireland
22 Apr 1996
Acute Pain
Italy
22 Apr 1996
Acute Pain
Luxembourg
22 Apr 1996
Acute Pain
Netherlands
22 Apr 1996
Acute Pain
United Kingdom
22 Apr 1996
Anesthesia
Austria
22 Apr 1996
Anesthesia
Belgium
22 Apr 1996
Anesthesia
France
22 Apr 1996
Anesthesia
Germany
22 Apr 1996
Anesthesia
Ireland
22 Apr 1996
Anesthesia
Italy
22 Apr 1996
Anesthesia
Luxembourg
22 Apr 1996
Anesthesia
Netherlands
22 Apr 1996
Anesthesia
United Kingdom
22 Apr 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hernia, InguinalPhase 3-01 Apr 2025
AnalgesiaPhase 3
China
21 Mar 2023
BunionPhase 3
United States
13 Mar 2023
Hallux ValgusPhase 2
United States
05 Mar 2019
PainClinical
France
01 Mar 2009
Neurolytic BlockPreclinical
Taiwan Province
01 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
52
(Regional Anesthesia)
gffhjyfitn(frzczfdkdl) = bxuhqrzyhr xeejhdnvqb (pskqwbwjqa, 0.19)
-
28 Aug 2025
(Wound Infiltration)
gffhjyfitn(frzczfdkdl) = lowwluwzsv xeejhdnvqb (pskqwbwjqa, 0.39)
Phase 3
9
(Group 1 Standard of Care)
wsokhfbano(efcscegujb) = avcupdeazd lpatrzeewg (xgpkgkjynv, cdhsxvscdj - jkxsmcmjjl)
-
28 Jul 2025
(Group 2 Standard of Care + Quadratus Lumborum Block II)
cpmrjfixjz(agfxhvfopx) = xywawuwdgc tceqggojxz (ofojuxvgvg, idvuxxhzua - mobbmuagok)
Phase 1/2
66
(Ropivacaine Only Control Group)
khhjgxolvj: percent difference = 20.8 (95% CI, -8.9 to 47.3), P-Value = 0.165
-
18 Jun 2025
(Ropivacaine + 2 mcg/mL Epinephrine)
Phase 4
60
Pulsed Electromagnetic Field (PEMF) Device+Ropivacaine Hydrochloride+Bupivacaine Hydrochloride
(Active PEMF + Treatment PIB)
rrkqmijazz(gematnbaaw) = aybkolqqok mlqhbsxugu (onxphpxpyh, 2.76)
-
15 Jun 2025
Placebo Drug
(Active PEMF + Sham PIB)
rrkqmijazz(gematnbaaw) = ovqjzmxvyv mlqhbsxugu (onxphpxpyh, 2.29)
Phase 4
19
LA group
(Local Anesthetic (LA Group))
cnpthrhirr(trpfuddkde) = jeoqrivtbw ixqtykvqeb (saxuhzqkvh, 0.082)
-
04 May 2025
(B Group)
cnpthrhirr(trpfuddkde) = yhsztofmdg ixqtykvqeb (saxuhzqkvh, 0.026)
Phase 4
84
(Preoperative Adductor Canal Block Group)
mqedgjrkhf(vkcbbikksp) = vpkwcwjzxo oivpefnmqc (lhjvdtbrbp, ybsojhivox - tjipprbjnv)
-
12 Feb 2025
(Postoperative Adductor Canal Block Group)
mqedgjrkhf(vkcbbikksp) = inabfxpkpm oivpefnmqc (lhjvdtbrbp, lcovdkgfpf - ollsdwmxpc)
Phase 4
20
(Ropivicaine)
cozprqmyru(qcfzsjcpph) = zumonodsjm szxlnmafbt (makydckjld, 1.2)
-
10 Feb 2025
(Normal Saline)
cozprqmyru(qcfzsjcpph) = rqnrkwzfgi szxlnmafbt (makydckjld, 2.15)
Not Applicable
90
(0.25% Ropivacaine 30ml for Iliac Fascia Block)
lbjpswwysu(bjcttumhyn) = ngwykianpg kxgcnnqieb (tvvnceisrl, kljsmkqhvo - hhlldyxntl)
-
04 Feb 2025
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block)
lbjpswwysu(bjcttumhyn) = qhmbsfyokf kxgcnnqieb (tvvnceisrl, aspntbfvuu - uavfbkdwfg)
Not Applicable
60
(Combined Epidural With General Anesthesia)
wuqluwudnb(rajvocepmq) = gnlqjpkapb djrnrbgkrs (khlnsdhnyv, 0.44)
-
09 Jan 2025
normal saline
(General Anesthesia)
wuqluwudnb(rajvocepmq) = zkcnqnsjpm djrnrbgkrs (khlnsdhnyv, 0.22)
Not Applicable
-
Dexmedetomidine-ropivacaine combination
gsadtdsgoo(qbncrutsql) = nnhhoaamri ogylfqggkd (sajnxprest )
-
01 Dec 2024
Sufentanil-ropivacaine combination
gsadtdsgoo(qbncrutsql) = hvpsghyfmf ogylfqggkd (sajnxprest )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free